Thanks Gekkowolf. Link to full finfeed article. Here are the pertinent paragraphs:

OncoSil on verge of CE Mark approval

By Trevor Hoey. Published at Feb 27, 2020, in Biotech

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd(ASX:OSL) with the company having flagged finalisation of commercialisation plans for its OncoSil^TM device in anticipation of CE marking early in 2020.

... ...

‘Overweight’: Upgrade anticipating European approval

On January 30, in an update on the company, Wilsons Equity Research confirmed that it has an optimistic view of OSL.

Wilsons moved further “OVERWEIGHT” on the stock in anticipation of the imminent European approval for OncoSil^TM, plus OncoSil’s pursuit of a humanitarian approval in the USA.

Wilsons lifted its 12-month target price to $0.30, a 122% premium to the current 13.5 cent share price. Plus, its signalled that catalysts over the next 3-4 years could support valuation gains up to $1.20 per share.

This valuation lift comes after Wilsons determined the probability of European approval to be 90%, up from 60% prior to receipt of the positive CE Mark Status Report. It also recognised that the clinical trial data supporting the OncoSil^TM product has continued to improve in terms of patient survival.

... ...

Institutional interest in OncoSil

The potential for OncoSil to quickly transition from device development to full commercialisation has been recognised by the market.

Merrill Lynch and its affiliates have been accumulating stock since mid-2019, but on-market purchasing of shares accelerated in October 2019, while Bank of America and related parties acquired a substantial shareholding of 5.6%, as announced in November.

Interestingly, the increased institutional support coincided with news embodied in the CE Mark update.

There has also been strong retail investor support, triggering a tripling in the group’s share price in October/November 2019.

The traditional lull in news flow during the December/January period saw a slight share price retracement, combined with the more recent market weakness see the stock trading in the vicinity of 14 cents.

This may represent a buying opportunity pending positive news regarding the CE Mark approval, which could be a significant share price catalyst.